NLS Pharmaceutics AG
NLSP
$1.47
-$0.053-3.48%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.52M | 5.21M | 5.90M | 6.21M | 6.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.31M | 9.06M | 11.81M | 13.08M | 14.34M |
| Operating Income | -6.31M | -9.06M | -11.81M | -13.08M | -14.34M |
| Income Before Tax | -6.60M | -9.38M | -12.17M | -13.82M | -15.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.60 | -9.38 | -12.17 | -13.82 | -15.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.60M | -9.38M | -12.17M | -13.82M | -15.47M |
| EBIT | -6.31M | -9.06M | -11.81M | -13.08M | -14.34M |
| EBITDA | -6.30M | -9.05M | -11.80M | -13.06M | -14.33M |
| EPS Basic | -6.72 | -9.74 | -12.75 | -17.06 | -21.36 |
| Normalized Basic EPS | -4.20 | -6.09 | -7.97 | -10.17 | -12.37 |
| EPS Diluted | -6.72 | -9.74 | -12.75 | -17.06 | -21.36 |
| Normalized Diluted EPS | -4.20 | -6.09 | -7.97 | -10.17 | -12.37 |
| Average Basic Shares Outstanding | 4.01M | 3.91M | 3.82M | 3.45M | 3.08M |
| Average Diluted Shares Outstanding | 4.01M | 3.91M | 3.82M | 3.45M | 3.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |